Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 4/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | LCAT | P04180 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7491396 | 1.00 | NOTUM (0.67) | NOTUMARDRD2DRD3LRRK2 | |
| SCHEMBL2732722 | 0.91 | DRD2 (0.64) | NOTUMARDRD2DRD3LRRK2 | |
| SCHEMBL21624920 | 0.82 | NOTUM (0.63) | NOTUMARDRD2DRD3LRRK2 | |
| SCHEMBL21624919 | 0.82 | NOTUM (0.63) | NOTUMARDRD2DRD3LRRK2 | |
| SCHEMBL320725 | 0.81 | AR (0.60) | NOTUMAR | |
| SCHEMBL10277569 | 0.81 | AR (0.60) | NOTUMAR | |
| SCHEMBL20076216 | 0.81 | AR (0.60) | NOTUMAR | |
| SCHEMBL25080875 | 0.78 | NOTUM (0.59) | NOTUMDRD2DRD3CHRM4 | |
| SCHEMBL25080895 | 0.78 | BPTF (0.64) | NOTUMDRD2DRD3CHRM4C1S | |
| SCHEMBL29012566 | 0.78 | BPTF (0.64) | NOTUMDRD2DRD3CHRM4C1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| EP-2121703-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008020799-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | NOTUM 2133/4885AR 4417/4885DRD2 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.